|Bid||170.38 x 2200|
|Ask||170.47 x 800|
|Day's range||169.75 - 180.71|
|52-week range||115.61 - 497.49|
|Beta (5Y monthly)||1.60|
|PE ratio (TTM)||5.41|
|Earnings date||02 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||221.40|
DGAP-News: Moderna, Inc. / Key word(s): MiscellaneousModerna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses 09.08.2022 / 12:40 CET/CESTThe issuer is solely responsible for the content of this announcement.Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses Contractually remain
MRNA vs. TECH: Which Stock Is the Better Value Option?
With the S&P 500 Index dipping as low as 23% within the past couple of months, we've hit the ballpark of bear market territory. Let's learn about three of the most common ways that bear markets create the very powerful temptation to sell so that you can resist the temptation when it calls. The most visible way that the bear market is likely to test investors' resolve is by demolishing the stocks of companies that were not too long ago put forward as high-flying success stories.